Literature DB >> 32162032

How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital.

Jie Zeng1, Jianxin Huang2, Lingai Pan3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32162032      PMCID: PMC7079823          DOI: 10.1007/s00134-020-05993-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   41.787


× No keyword cloud information.
Dear Editor, Acute myocardial infarction (AMI) is a cardiovascular emergency and requires an emergency diagnosis and treatment process. Unfortunately, the highly contagious COVID-19 pneumonia is obviously affecting the diagnosis and treatment of acute myocardial infarction (AMI) which includes ST-elevated myocardial infarction (STEMI) and non-ST-segment elevation acute myocardial infarction (NSTEMI). There are increasing confirmed cases around multiple countries every day. The transmission dynamics is not fully understood [1]. It is necessary to adjust the routine diagnosis and treatment protocol of AMI to face the serious public health event.

General principles

The emergency call should instruct patients to choose the nearest center that can complete primary percutaneous coronary intervention (PCI) treatment. Avoid public transportation. Adopt the principle of maximum protection. Patients with AMI accompanied by fever, especially respiratory symptoms, should first go to a fever outpatient clinic. Combined with epidemiological history and body temperature screening, if suspected of SARS-CoV-2 infection, they will be admitted to the hospital isolation ward for rapid nucleic acid test. The nucleic acid test can significantly delay the time of STEMI emergency reperfusion. Patients suspected or diagnosed with SARS-CoV-2 infection should be isolated and begin thrombolytic therapy immediately, if within reperfusion time. High-risk patients with contraindications for thrombolysis need to assess the risk of infection and the benefit of PCI. Perform PCI only for culprit vessel.

Protocol for STEMI

Perform the following management: [Fig. 1a: Partial reference to “Diagnosis and treatment process of acute myocardial infarction in the prevention and control of coronavirus Chinese expert advice (first edition)”].
Fig. 1

Protocol of a STEMI, b NSTEMI

Stable patients when the onset time is within 12 h. In case of patients within the reperfusion time window and no contraindication to thrombolysis, thrombolytic therapy is performed in an isolation ward. After successful thrombolysis, treatment is continued in the isolation ward. After the patient has recovered from COVID-19 pneumonia and test of nucleic acid is twice negative, elective PCI should be considered. Patients within the reperfusion time window with contraindications for thrombolysis or failure of thrombolysis need to comprehensively evaluate the risks of PCI and infection control. Stable patients when the onset time is more than 12 h: comprehensively evaluate the risks of PCI and infection control. Unstable patients with severe pneumonia. Transfer to isolation ward for conservative treatment. Unstable patients with mild to moderate pneumonia: assess whether the onset time of STEMI is longer than 12 h. The subsequent steps are the same as those for STEMI patients with stable vital signs. Perform echocardiography and ECG 24–48 h after the reperfusion therapy. If the patient is stable, rapid rehabilitation should be performed to shorten the hospitalization time as much as possible. Follow-up should be performed through the internet outpatient clinic of Sichuan Provincial People’s Hospital. Protocol of a STEMI, b NSTEMI

Protocol for NSTEMI

The door-to-balloon time in NSTMI patients is less strict than that in STEMI patients. Therefore, we should exclude the SARS-CoV-2 infection first (Fig. 1b). The confirmed case should be transferred to the isolation ward until patient recovery and then it was assessed whether further invasive interventions are needed. Very few NSTEMI patients may present hemodynamic instability and fatal arrhythmia who cannot wait for the results of nucleic acid tests, and then, the isolated intervention surgery should be the first choice.
  1 in total

1.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

  1 in total
  74 in total

Review 1.  Effects of Covid-19 outbreak on environment and renewable energy sector.

Authors:  Hasan Eroğlu
Journal:  Environ Dev Sustain       Date:  2020-06-28       Impact factor: 3.219

2.  Cardiovascular view of intermediate and high-risk COVID-19 patients: single-centre experience with low mortality and intensive care hospitalisation rates.

Authors:  Alpay Medetalibeyoglu; Samim Emet; Naci Senkal; Mehmet Aydogan; Murat Kose; Tufan Tukek
Journal:  Cardiovasc J Afr       Date:  2020-11-09       Impact factor: 1.167

3.  Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.

Authors:  Mustafa Yolcu; Fusun Gunesdogdu; Metin Bektas; Derya Turan Bayirli; Kivanc Serefhanoglu
Journal:  Cardiovasc J Afr       Date:  2020-05-05       Impact factor: 1.167

Review 4.  Artificial intelligence as a fundamental tool in management of infectious diseases and its current implementation in COVID-19 pandemic.

Authors:  Ishnoor Kaur; Tapan Behl; Lotfi Aleya; Habibur Rahman; Arun Kumar; Sandeep Arora; Israt Jahan Bulbul
Journal:  Environ Sci Pollut Res Int       Date:  2021-05-25       Impact factor: 4.223

5.  Complicated myocardial infarction in a 99-year-old lady in the era of COVID-19 pandemic: from the need to rule out coronavirus infection to emergency percutaneous coronary angioplasty.

Authors:  Fabio Alfredo Sgura; Salvatore Arrotti; Carlo Giuseppe Cappello; Giuseppe Boriani
Journal:  Intern Emerg Med       Date:  2020-05-13       Impact factor: 3.397

Review 6.  Investigating the implications of COVID-19 outbreak on systems of care and outcomes of STEMI patients: A systematic review and meta-analysis.

Authors:  William Kamarullah; Adelia Putri Sabrina; Marthin Alexander Rocky; Darius Revin Gozali
Journal:  Indian Heart J       Date:  2021-06-25

7.  Performance of Primary Angioplasty for STEMI during the COVID-19 Outbreak.

Authors:  Surya Dharma; Iwan Dakota; Isman Firdaus; Siska Suridanda Danny; Dian Zamroni; Ardi Yudha; Agus Susanto; Bambang Budi Siswanto
Journal:  Int J Angiol       Date:  2021-04-20

Review 8.  COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.

Authors:  Yasar Sattar; Waqas Ullah; Hiba Rauf; Hafeez Ul Hassan Virk; Sunita Yadav; Medhat Chowdhury; Michael Connerney; Sahil Mamtani; Mohit Pahuja; Raj D Patel; Tanveer Mir; Talal Almas; Homam Moussa Pacha; M Chadi Alraies
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-14

Review 9.  Cardiovascular disease management during the coronavirus disease 2019 pandemic.

Authors:  Wen-Hsien Lee; Ying-Chih Chen; Szu-Chia Chen; Chang-Jen Chen; Po-Chao Hsu; Wei-Chung Tsai; Chun-Yuan Chu; Chee-Siong Lee; Tsung-Hsien Lin; Wen-Chol Voon; Chao-Hung Kuo; Ho-Ming Su
Journal:  Int J Med Sci       Date:  2020-05-29       Impact factor: 3.738

10.  Italian Society of Interventional Cardiology (GISE) position paper for Cath lab-specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID-19.

Authors:  Giuseppe Tarantini; Chiara Fraccaro; Alaide Chieffo; Alfredo Marchese; Fabio Felice Tarantino; Stefano Rigattieri; Ugo Limbruno; Ciro Mauro; Alessio La Manna; Battistina Castiglioni; Matteo Longoni; Sergio Berti; Francesco Greco; Giuseppe Musumeci; Giovanni Esposito
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-11       Impact factor: 2.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.